ICON Public (NASDAQ:ICLR) PT Raised to $362.00

ICON Public (NASDAQ:ICLR - Get Free Report) had its price objective boosted by equities researchers at Robert W. Baird from $345.00 to $362.00 in a report released on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the medical research company's stock. Robert W. Baird's price objective would indicate a potential upside of 15.59% from the company's current price.

A number of other equities research analysts have also issued reports on the stock. Citigroup upped their price objective on shares of ICON Public from $300.00 to $315.00 and gave the company a "buy" rating in a report on Monday, December 11th. Barclays upped their price objective on shares of ICON Public from $325.00 to $355.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. Evercore ISI upped their price objective on shares of ICON Public from $325.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, February 23rd. Truist Financial upped their price objective on shares of ICON Public from $357.00 to $367.00 and gave the company a "buy" rating in a report on Friday, February 23rd. Finally, Mizuho reaffirmed a "buy" rating and set a $346.00 target price on shares of ICON Public in a research note on Thursday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, ICON Public has an average rating of "Moderate Buy" and a consensus target price of $319.45.

ICON Public Price Performance

NASDAQ ICLR traded down $7.91 on Thursday, hitting $313.18. The company had a trading volume of 508,573 shares, compared to its average volume of 565,600. The company has a market capitalization of $25.84 billion, a PE ratio of 42.44, a PEG ratio of 1.52 and a beta of 1.15. The company's fifty day moving average price is $308.48 and its 200-day moving average price is $276.51. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21. ICON Public has a 12-month low of $181.92 and a 12-month high of $344.77.

ICON Public (NASDAQ:ICLR - Get Free Report) last released its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.27 by $0.13. ICON Public had a net margin of 7.54% and a return on equity of 11.42%. The business had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.08 billion. As a group, analysts predict that ICON Public will post 14.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ICLR. Bruce G. Allen Investments LLC acquired a new position in shares of ICON Public during the 4th quarter valued at about $25,000. LM Advisors LLC acquired a new position in shares of ICON Public during the 4th quarter valued at about $26,000. Livelsberger Financial Advisory acquired a new position in shares of ICON Public during the 4th quarter valued at about $29,000. Pinnacle Bancorp Inc. increased its stake in shares of ICON Public by 110.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company's stock valued at $30,000 after acquiring an additional 55 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of ICON Public during the 4th quarter valued at about $37,000. Institutional investors and hedge funds own 95.61% of the company's stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.